Briacell Therapeutics CorpNASDAQ:BCTXView on Canadian Exchange
- LAST PRICE2.0200
- TODAY'S CHANGE (%)-0.1276 (-5.9415%)
- Bid / Lots2.0000/ 6
- Ask / Lots2.1600/ 4
- Open / Previous Close2.1750 / 2.1476
- Day Range
- 52 Week Range
- Volume41,777
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BCTX |
|---|---|---|
| 09:36 ET | 100 | 2.175 |
| 09:48 ET | 814 | 2.19 |
| 10:15 ET | 1300 | 2.23 |
| 10:21 ET | 200 | 2.29 |
| 10:24 ET | 100 | 2.29 |
| 11:11 ET | 199 | 2.266 |
| 11:56 ET | 400 | 2.23 |
| 12:05 ET | 140 | 2.23 |
| 12:07 ET | 229 | 2.206 |
| 01:03 ET | 3000 | 2.19 |
| 01:06 ET | 111 | 2.18 |
| 02:24 ET | 6730 | 2.16 |
| 02:36 ET | 8625 | 2.13 |
| 02:49 ET | 200 | 2.1 |
| 02:56 ET | 1680 | 2.14 |
| 03:20 ET | 385 | 2.1 |
| 03:25 ET | 500 | 2.095 |
| 03:32 ET | 100 | 2.09 |
| 03:36 ET | 500 | 2.0627 |
| 03:43 ET | 100 | 2.0601 |
| 03:48 ET | 100 | 2.05 |
| 03:52 ET | 104 | 2.0552 |
| 03:54 ET | 198 | 2.06 |
| 03:56 ET | 10173 | 2.01 |
| 03:57 ET | 601 | 2.05 |
| 03:59 ET | 1100 | 2.02 |
Apr 10, 2024
Apr 9, 2024
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR, from 8:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Briacell Therapeutics Corp | 47.1M | 0.0x | --- |
Company Information
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.
Contact Information
- Headquarters
- 3rd Floor Bellevue Centre,, 235-15th StrWEST VANCOUVER, BC, Canada V7T 2X1
- Phone
- 604-921-1810
- Fax
- 604-921-1898
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $47.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 16.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.80 |
EPS | $-1.12 |
Book Value | $-0.33 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
